Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juni 2023

Genmab — Juni 2023

Planlagt Fastgjort Låst Flyttet Genmab
702 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Sukkeralf
    wrote on sidst redigeret af
    #496

    Just a moment...

    favicon

    (firstwordpharma.com)

    1 Reply Last reply
    0
    • P Offline
      P Offline
      ProinvestorNEWS
      wrote on sidst redigeret af
      #497

      Shortpositioner på danske aktier https://www.proinvestor.com/boards/113385

      1 Reply Last reply
      0
      • K Offline
        K Offline
        Klarussen
        wrote on sidst redigeret af
        #498

        Tid til defensive aktier igen?

        1 Reply Last reply
        0
        • K Offline
          K Offline
          Klarussen
          wrote on sidst redigeret af
          #499

          Genmab meget stabilt på short 0,43%

          1 Reply Last reply
          0
          • R Offline
            R Offline
            Riis7
            wrote on sidst redigeret af
            #500

            Kan Genmab ikke stige 2 dage i træk:-) kom nu

            1 Reply Last reply
            0
            • B Offline
              B Offline
              bikube
              wrote on sidst redigeret af
              #501

              Jo det kan den da - bare se, hvad der skete for et år siden, vi skal bare have fundet det rigtige udgangspunkt. Hvad var det for øvrigt, der startede opturen 16.juni sidste år.

              1 Reply Last reply
              0
              • R Offline
                R Offline
                Riis7
                wrote on sidst redigeret af
                #502

                Det bliver nok ikke i dag;-)

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #503

                  EPCORE DLBCL-1 seems fully recruited. They are extending the duratoin of the trial by 4 years. Outcomes will now be measured for 5 years instead of the intended 2 years. How should i read this? Is this a requirement by the FDA? Or are they now thinking patients could still be active on Epco after 5 years instead of 2? https://classic.clinicaltrials.gov/ct2/history/NCT04628494?B=24&A=23&C=merged#StudyPageTop

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #504

                    GEN1042, 3009 and 3014 were also updated btw

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #505

                      Case report: Successful treatment with daratumumab for pure red cell aplasia in a patient with mixed lymphoid chimerism after ABO-mismatched stem cell transplant for sickle cell disease https://www.frontiersin.org/articles/10.3389/fimmu.2023.1212007/full?utm_source=S-TWT&utm_medium=SNET&utm_campaign=ECO_FIMMU_XXXXXXXX_auto-dlvrit

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #506

                        E L regarding EPCORE DLBCL-1 study must be because it works better than expected…….possibility for cures maybe. But if they cant file based on interim data then it kind of sucks.

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #507

                          Her er det så vi savner en q&a. Vi er afhængige af om nogen spørger ind til det på cc. Hvid de først kan file på RR i 2028 bliver det en langtrækker med epco.

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #508

                            I hope you are right @Sukkeralf . I do believe interim data can be sufficient for filing

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #509

                              $XBI Big Biotech #Outflows Return
                              ~$894M of net outflows
                              This is the #second #largest week of outflows for the sector this year and marks
                              the 19th week of outflows out of 25 total weeks in 2023. YTD net fund flow now stands
                              at ~$7.2B in outflows. https://twitter.com/BiotechAnalysst/status/1672236857281716225

                              1 Reply Last reply
                              0
                              • R Offline
                                R Offline
                                Riis7
                                wrote on sidst redigeret af
                                #510

                                folk sælger ud af pharma biotek, har de gjort det meste af 2023, folk vil ha tech i år

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #511

                                  Enig Riis.Tendensen er klart i den retning.

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #512

                                    TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED) https://ir.horizontherapeutics.com/news-releases/news-release-details/tepezzar-teprotumumab-approved-brazil-treatment-active-thyroid

                                    1 Reply Last reply
                                    0
                                    • BulderB Offline
                                      BulderB Offline
                                      Bulder
                                      wrote on sidst redigeret af
                                      #513

                                      Sammenligner man med øvrig medicinal i dag, må gmabs fald siges at være behersket.

                                      1 Reply Last reply
                                      0
                                      • L Offline
                                        L Offline
                                        lahn1
                                        wrote on sidst redigeret af
                                        #514

                                        Adicet nede med 50% efter PH1 data i r/r B-cell NHL https://investor.adicetbio.com/news-releases/news-release-details/adicet-bio-reports-positive-data-ongoing-adi-001-phase-1-trial-0

                                        1 Reply Last reply
                                        0
                                        • BulderB Offline
                                          BulderB Offline
                                          Bulder
                                          wrote on sidst redigeret af
                                          #515

                                          ?? Data ser da fine ud.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper